Obesity Ups Prostate Cancer Risks Before and After Surgery

Chairman of Urology, Chief of Robotic Surgery at Lenox Hill

New York, NY, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Obesity and prostate cancer are two of the most prevalent conditions among U.S. men. One in six will be diagnosed with prostate cancer; one in three are obese. Not only are obese men more likely to be diagnosed with prostate cancer, excess weight makes prostate cancer treatment and the road to recovery much more difficult.

Dr. Samadi is the Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital. As a board-certified urologist and an oncologist specializing in the diagnosis and treatment of urologic diseases, kidney cancer, bladder cancer, and prostate cancer, he also specializes in many advanced minimally invasive treatments for prostate cancer, including his innovative robotic surgery procedure, SMART (Samadi Modified Advanced Robotic Technique) Surgery. More information about Dr. Samadi can be found on his website, http://www.roboticoncology.com/


World-renowned robotic prostate surgeon, Dr. David Samadi, offers these men good news in the form of surgical opportunity. As Chairman of Urology, Chief of Robotic Surgery at Lenox Hill Hospital and Professor of Urology at Hofstra North Shore-LIJ School of Medicine, Dr. Samadi is one of very few high-risk robotic prostate surgery experts adept at managing the increased complications of obese men with prostate cancer.

Using a custom robotic procedure, SMART (Samadi Modified Advanced Robotic Technique) surgery, Dr. Samadi continually demonstrates surgical success among obese men. Highly sought after, Dr. Samadi has performed more than 5,000 successful robotic prostate surgeries. His minimally invasive procedure and high surgical volume give obese men the same fighting chance as their average-weight counterparts.

"Prostate cancer and obesity are two distinct diseases," explains Dr. Samadi. "An obese man's body is already taxed, often with metabolic syndrome. Adding aggressive prostate cancer to the mix challenges both the patient and the surgeon. With SMART Surgery, we're able to overcome many of those challenges."

Researchers continue to document the high stakes of obesity and prostate cancer.

· Prostate cancer risk increases by as much as 57%

· Gleason score, prostate size, and prostate cancer tumor volume all increase

· Prostate surgery complications jump

· Erectile dysfunction (ED) and urinary incontinence after surgery are more likely

A recent Italian study published in Renal & Urology News, http://www.renalandurologynews.com/prostate-cancer-surgery-outcomes-worse-in-obese-men/article/302300/#, found men with abdominal obesity to have a greater risk of intraoperative complications and blood transfusions associated with larger cancer volume and heightened disease aggressiveness.

Earlier 2013 studies also highlight the obesity-prostate cancer connection:

http://www.roboticoncology.com/pdf/AUA%20Metabolic%20Syndrome%20Abstract.pdf and http://cebp.aacrjournals.org/content/early/2013/04/22/1055-9965.EPI-12-0965.abstract.

"Obesity damages far more than the waistline and it is one of few avoidable risk factors," stresses Dr. Samadi. "Maintaining a healthy weight can ward off a number of diseases and optimize the body's fighting power when they do present."

Dr. Samadi's SMART surgery has a proven track record of success in prostate cancer cure rates, sexual potency after surgery, and urinary control after surgery. In his hands, obese men can achieve comparable robotic prostate surgery results to non-obese men.

A photo accompanying this release is available at:

CONTACT: David B. Samadi, M.D Chairman of Urology, Chief of Robotic Surgery at Lenox Hill Hospital Professor of Urology at Hofstra North Shore-LIJ School of Medicine Tel: 1-212-365-5000 Address: 485 Madison Avenue (between 51st-52nd street) 21st floor New York, NY 10022 http://www.roboticoncology.com/contact/

Source: RoboticOncology